Allogene Therapeutics Inc (NASDAQ: ALLO) has experienced a rise in its stock price by 2.69 compared to its previous closing price of 1.30. However, the company has seen a fall of -7.93% in its stock price over the last five trading days. zacks.com reported 2025-06-12 that Allogene Therapeutics (ALLO) reported earnings 30 days ago. What’s next for the stock?
Is It Worth Investing in Allogene Therapeutics Inc (NASDAQ: ALLO) Right Now?
The 36-month beta value for ALLO is also noteworthy at 0.31. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 4 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for ALLO is 149.51M, and at present, short sellers hold a 16.43% of that float. The average trading volume of ALLO on June 18, 2025 was 3.23M shares.
ALLO’s Market Performance
The stock of Allogene Therapeutics Inc (ALLO) has seen a -7.93% decrease in the past week, with a 22.48% rise in the past month, and a -21.01% fall in the past quarter. The volatility ratio for the week is 3.37%, and the volatility levels for the past 30 days are at 4.55% for ALLO. The simple moving average for the past 20 days is 4.64% for ALLO’s stock, with a -33.58% simple moving average for the past 200 days.
Analysts’ Opinion of ALLO
Citizens JMP, on the other hand, stated in their research note that they expect to see ALLO reach a price target of $5. The rating they have provided for ALLO stocks is “Mkt Outperform” according to the report published on March 14th, 2025.
Oppenheimer gave a rating of “Outperform” to ALLO, setting the target price at $11 in the report published on August 08th of the previous year.
ALLO Trading at -0.25% from the 50-Day Moving Average
After a stumble in the market that brought ALLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.68% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALLO starting from MESSEMER DEBORAH M., who sale 36,885 shares at the price of $1.42 back on Jun 10 ’25. After this action, MESSEMER DEBORAH M. now owns 107,431 shares of Allogene Therapeutics Inc, valued at $52,377 using the latest closing price.
MESSEMER DEBORAH M., the Director of Allogene Therapeutics Inc, proposed sale 36,885 shares at $1.42 during a trade that took place back on Jun 10 ’25, which means that MESSEMER DEBORAH M. is holding shares at $52,391 based on the most recent closing price.
Stock Fundamentals for ALLO
Current profitability levels for the company are sitting at:
- 12222.09 for the present operating margin
- 1.0 for the gross margin
The net margin for Allogene Therapeutics Inc stands at 11469.23. The total capital return value is set at -0.56. Equity return is now at value -59.60, with -46.11 for asset returns.
Based on Allogene Therapeutics Inc (ALLO), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -2.43. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is -812.34.
Currently, EBITDA for the company is -243.33 million with net debt to EBITDA at -0.16. When we switch over and look at the enterprise to sales, we see a ratio of -15038.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.71.
Conclusion
In summary, Allogene Therapeutics Inc (ALLO) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
